CN114729354A - 炎性相关疾病防治的小rna药物及其组合 - Google Patents

炎性相关疾病防治的小rna药物及其组合 Download PDF

Info

Publication number
CN114729354A
CN114729354A CN201880100050.3A CN201880100050A CN114729354A CN 114729354 A CN114729354 A CN 114729354A CN 201880100050 A CN201880100050 A CN 201880100050A CN 114729354 A CN114729354 A CN 114729354A
Authority
CN
China
Prior art keywords
tnf
cell
small rna
1beta
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880100050.3A
Other languages
English (en)
Inventor
蒋澄宇
金宁一
赵丹丹
秦宇豪
张聪
林烨暄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Basic Medical Sciences of CAMS
Original Assignee
Institute of Basic Medical Sciences of CAMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Basic Medical Sciences of CAMS filed Critical Institute of Basic Medical Sciences of CAMS
Publication of CN114729354A publication Critical patent/CN114729354A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell

Abstract

提供了小RNA、包含小RNA的组合物以及其使用方法和用途。所述小RNA或组合物可以抑制表3中列出的任一种或多种通路或基因的能力或在体内或体外降低或下调IL‑1beta、IL‑6或/和TNF‑alpha的表达水平或治疗或预防受试者中IL‑1beta、IL‑6或/和TNF‑alpha相关疾病和/或提高细胞生存率。

Description

PCT国内申请，说明书已公开。

Claims (25)

  1. PCT国内申请，权利要求书已公开。
CN201880100050.3A 2018-12-25 2018-12-25 炎性相关疾病防治的小rna药物及其组合 Pending CN114729354A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/123289 WO2020132844A1 (zh) 2018-12-25 2018-12-25 炎性相关疾病防治的小rna药物及其组合

Publications (1)

Publication Number Publication Date
CN114729354A true CN114729354A (zh) 2022-07-08

Family

ID=71126734

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880100050.3A Pending CN114729354A (zh) 2018-12-25 2018-12-25 炎性相关疾病防治的小rna药物及其组合

Country Status (5)

Country Link
US (1) US20230272402A1 (zh)
EP (1) EP3960858A4 (zh)
CN (1) CN114729354A (zh)
CA (1) CA3124730A1 (zh)
WO (1) WO2020132844A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115350187A (zh) * 2022-08-30 2022-11-18 中山大学 异丙托溴铵在抑制肺癌骨转移中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023143480A1 (zh) * 2022-01-28 2023-08-03 中国医学科学院基础医学研究所 抑制癌细胞活性的小rna药物
CN114645050B (zh) * 2022-05-07 2024-02-23 贵州大学 一种miRNA及其在制备治疗乳腺癌的药物中的应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006060598A2 (en) * 2004-12-01 2006-06-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN AND INTERLEUKIN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010129919A1 (en) * 2009-05-08 2010-11-11 Research Development Foundation Mirna expression in allergic disease
WO2013181613A1 (en) * 2012-05-31 2013-12-05 Research Development Foundation Mirna for the diagnosis and treatment of autoimmune and inflammatory disease
CN103757020A (zh) * 2014-01-09 2014-04-30 浙江大学 用于调控烟草尼古丁合成和转运的基因及其应用
CN106687120A (zh) * 2014-04-30 2017-05-17 埃德蒙马赫基金会 一种用作免疫抑制剂的植物sRNA提取物
EP3216869A1 (en) * 2016-03-09 2017-09-13 Colizzi, Vittorio Nutraceutical plant derived microrna elements for treatment of cancer
US20170268047A1 (en) * 2016-03-18 2017-09-21 Norgen Biotek Corp. Methods and kits for separating nucleic acids by size
WO2018177383A1 (zh) * 2017-03-29 2018-10-04 中国医学科学院基础医学研究所 化合物或中药提取物在制备核酸递送试剂中的应用及其相关产品
CN109023536A (zh) * 2018-06-28 2018-12-18 河南师范大学 一种植物降解组文库构建方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CZ292465B6 (cs) 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
CZ291386B6 (cs) 1996-02-13 2003-02-12 Zeneca Limited Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP1301498A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
US20050277627A1 (en) 2000-07-07 2005-12-15 Arnould Jean C Colchinol derivatives as vascular damaging agents
DK2561078T3 (en) 2010-04-23 2019-01-14 Cold Spring Harbor Laboratory NEW STRUCTURALLY DESIGNED SHRNAs
KR101870915B1 (ko) * 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006060598A2 (en) * 2004-12-01 2006-06-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN AND INTERLEUKIN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010129919A1 (en) * 2009-05-08 2010-11-11 Research Development Foundation Mirna expression in allergic disease
WO2013181613A1 (en) * 2012-05-31 2013-12-05 Research Development Foundation Mirna for the diagnosis and treatment of autoimmune and inflammatory disease
CN103757020A (zh) * 2014-01-09 2014-04-30 浙江大学 用于调控烟草尼古丁合成和转运的基因及其应用
CN106687120A (zh) * 2014-04-30 2017-05-17 埃德蒙马赫基金会 一种用作免疫抑制剂的植物sRNA提取物
EP3216869A1 (en) * 2016-03-09 2017-09-13 Colizzi, Vittorio Nutraceutical plant derived microrna elements for treatment of cancer
US20170268047A1 (en) * 2016-03-18 2017-09-21 Norgen Biotek Corp. Methods and kits for separating nucleic acids by size
WO2018177383A1 (zh) * 2017-03-29 2018-10-04 中国医学科学院基础医学研究所 化合物或中药提取物在制备核酸递送试剂中的应用及其相关产品
CN109023536A (zh) * 2018-06-28 2018-12-18 河南师范大学 一种植物降解组文库构建方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
向静;黄洁嫦;徐畅;何免;徐鹏程;张丹;张文峰;沈晗;邵红伟;: "甘草水提物中miRNA对人免疫细胞基因表达的影响", no. 09, pages 1752 - 1756 *
马月;胡毅翔;张欢欢;俞文英;余陈欢;应华忠;: "地黄药效microRNAs的鉴定及其靶基因功能分析", no. 04, pages 416 - 420 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115350187A (zh) * 2022-08-30 2022-11-18 中山大学 异丙托溴铵在抑制肺癌骨转移中的应用
CN115350187B (zh) * 2022-08-30 2023-08-29 中山大学 异丙托溴铵在抑制肺癌骨转移中的应用

Also Published As

Publication number Publication date
US20230272402A1 (en) 2023-08-31
WO2020132844A1 (zh) 2020-07-02
CA3124730A1 (en) 2020-07-02
EP3960858A4 (en) 2023-02-15
EP3960858A1 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
Liu et al. Sinomenine inhibits the progression of rheumatoid arthritis by regulating the secretion of inflammatory cytokines and monocyte/macrophage subsets
CN101948539B (zh) Il-18结合蛋白
EP3463482B1 (en) Methods relating to t peripheral helper cells in autoantibody-associated conditions
CN114729354A (zh) 炎性相关疾病防治的小rna药物及其组合
TW200803895A (en) Method of using IL6 antagonists with proteasome inhibitors
US11779604B2 (en) Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN104870013A (zh) 用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂
US20230235070A1 (en) Method of treatment of inflammatory bowel disease using anti-tl1a antibodies
WO2020214650A1 (en) Methods and compositions for modulating the immune system
TW201922704A (zh) 作為免疫調節劑之氘化化合物
US20220220223A1 (en) Treatment of allergic diseases with chimeric protein
CN106459181A (zh) α‑烯醇化酶特异性抗体及其在免疫疾病治疗中的使用方法
WO2020073917A1 (en) Anti-bcma antibodies
TW202128160A (zh) 用於治療病原性血管病症之方法及組合物
EP3146966A1 (en) Pidotimod for use in the treatment of inflammation-associated diseases
CN101701218A (zh) 一种抑制Th1和Th17分化的免疫调节性寡聚脱氧核苷酸及应用
WO2022076573A1 (en) Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
Mekhemar et al. Toll-like receptors: The key of immunotherapy in MSCs
WO2019133711A1 (en) Methods of cancer treatment using an atr inhibitor
US20230159649A1 (en) Methods and combinations for dual targeting of tnf family members
US20240122985A1 (en) Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US20220378878A1 (en) Treatment of gastrointestinal disease
Sabree Evaluating the Complexity of the Immune Response to Vidutolimod: A Virus-Like Particle Containing a TLR9 Agonist
Garg Feedback inhibition of IL-17 receptor signal transduction
Huang Immune modulators with parasite infections

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination